Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8439-8446

  Kraus, Theo F J ^a   Kolck, Gesa ^a   Greiner, Andrea ^a   Schierl, Katharina ^a   Guibourt, Virginie ^a   Kretzschmar, Hans A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

5 hydroxymethylome; 5hmC; Brain tumor; Epigenetic; GBM; Glioblastoma

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY KI 67; NUCLEAR PROTEIN; PROTEIN H3S10P; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA LIGASE; DNA METHYLTRANSFERASE; HISTONE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; KI 67 ANTIGEN; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BRAIN CORTEX; CANCER INFILTRATION; CELL PROLIFERATION; CEREBELLUM; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN METHYLATION; WHITE MATTER; AGED; ANALOGS AND DERIVATIVES; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROMOTER REGION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYTOSINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; FEMALE; GLIOBLASTOMA; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84949089574     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3606-9     Document Type: Article

References (33)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
2. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Group Rw: epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532–42.
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14 Suppl 5:v1–49.
4. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110:4009–14.
5. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401.
6. Aubry M, de Tayrac M, Etcheverry A, Clavreul A, Saikali S, Menei P, et al. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget. 2015.
7. Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M, et al. Low values of 5-hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumors. Int J Cancer J Int du Cancer. 2012;131:1577–90.
8. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–30.
9. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. TET-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333:1303–7.
10. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. TET proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–3.
11. Pfaffeneder T, Hackner B, Truss M, Munzel M, Muller M, Deiml CA, et al. The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem. 2011;50:7008–12.
12. Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PW, Bauer C, et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell. 2013;152:1146–59.
13. Dongol S, Thompson CN, Clare S, Nga TV, Duy PT, Karkey A, et al. The microbiological and clinical characteristics of invasive salmonella in gallbladders from cholecystectomy patients in Kathmandu, Nepal. PLoS One. 2012;7, e47342.
14. Wu H, D’Alessio AC, Ito S, Wang Z, Cui K, Zhao K, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 2011;25:679–84.
15. Wu H, D’Alessio AC, Ito S, Xia K, Wang Z, Cui K, et al. Dual functions of TET1 in transcriptional regulation in mouse embryonic stem cells. Nature. 2011;473:389–93.
16. Yildirim O, Li R, Hung JH, Chen PB, Dong X, Ee LS, et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell. 2011;147:1498–510.
17. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell. 2012;151:1417–30.
18. Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry. 2011;82:441–6.
19. Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol. 2009;68:1219–28.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
21. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G: radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
22. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5:198–206.
23. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G: effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
24. Knisely JP, Baehring JM. A silver lining on the horizon for glioblastoma. Lancet Oncol. 2009;10:434–5.
25. Intergroup Radiation Therapy Oncology Group T, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:2707–14.
26. Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-Oncology. 2012;14:1473–80.
27. Torp SH. Proliferative activity in human glioblastomas: evaluation of different Ki67 equivalent antibodies. Mol Pathol. 1997;50:198–200.
28. Torp SH. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol. 2002;21:252–7.
29. Ribeiro-Mason K, Boulesteix C, Fleurot R, Aguirre-Lavin T, Adenot P, Gall L, et al. H3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage. J Reprod Dev. 2012;58:467–75.
30. Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, et al. 5-HMC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci. 2011;14:1607–16.
31. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.
32. Kunimoto H, Fukuchi Y, Sakurai M, Takubo K, Okamoto S, Nakajima H. TET2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity. Blood. 2014;123:2897–9.
33. Nakajima H, Kunimoto H. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci. 2014;105:1093–9.